High expression of Ki-67 acts a poor prognosis indicator in locally advanced nasopharyngeal carcinoma

Biochem Biophys Res Commun. 2017 Dec 9;494(1-2):390-396. doi: 10.1016/j.bbrc.2017.09.118. Epub 2017 Sep 22.

Abstract

Nasopharyngeal carcinoma (NPC) is a common head and neck malignancy in Southern China and Southeast Asia compared with Western countries. The standard treatment for NPC is radiotherapy. However, radioresistance remains a serious obstacle to satisfactory treatment, it can cause local recurrence and distant metastases in some patients after treatment by radiation. We retrospectively reviewed 108 NPC patients (7th AJCC Ⅲ-Ⅳa) who have received intensity modulated radiation therapy (IMRT) between August 2008 and January 2012 at Xiangya Hospital of Central South University. Ninety-eight patients with >60% reduction of tumor size after radiation treatment were regarded as radiation sensitive, Ten patients with <40% reduction of tumor size after radiation treatment were regarded as radiation resistant. Using immunohistochemistry, we found that the high expression rate of Ki-67 in radiation resistant and radiation sensitive patients was 80.0% and 42.6%, respectively, and the difference was statistically significant (p = 0.025). The 5-year progress free survival rates in patients with low and high expression of Ki-67 was 70.7% and 48.0%, respectively, and the difference was statistically significant (p = 0.0008). Multivariate Cox regression analysis identified that high expression of Ki-67 was an independent negative prognostic factor in nasopharyngeal carcinoma patients [Hazard ratio (95% CI), 2.098(1.101, 3.996); p = 0.024]. These results demonstrate that high expression of Ki-67 contributes to radiation resistance and acts a poor prognosis indicator in patients with locally advanced nasopharyngeal carcinoma.

Keywords: Immunohistochemistry; Ki-67; Local advanced nasopharyngeal carcinoma; Radiation resistance.

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • Antibodies, Monoclonal, Humanized / therapeutic use
  • Antineoplastic Agents / therapeutic use
  • Biomarkers, Tumor / genetics*
  • Biomarkers, Tumor / metabolism
  • Carcinoma / diagnosis*
  • Carcinoma / genetics*
  • Carcinoma / mortality
  • Carcinoma / therapy
  • Cetuximab / therapeutic use
  • Female
  • Gamma Rays / therapeutic use
  • Humans
  • Ki-67 Antigen / genetics*
  • Ki-67 Antigen / metabolism
  • Male
  • Middle Aged
  • Nasopharyngeal Carcinoma
  • Nasopharyngeal Neoplasms / diagnosis*
  • Nasopharyngeal Neoplasms / genetics*
  • Nasopharyngeal Neoplasms / mortality
  • Nasopharyngeal Neoplasms / therapy
  • Neoplasm Staging
  • Prognosis
  • Retrospective Studies
  • Survival Analysis

Substances

  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents
  • Biomarkers, Tumor
  • Ki-67 Antigen
  • Mki67 protein, mouse
  • nimotuzumab
  • Cetuximab